Zydus gets final approval for Clobetasol Propionate Lotion

Cadila Healthcare informed the exchanges on Thursday that Zydus Cadila has received the final approval from the USFDA to market Clobetasol Propionate Lotion, (US RLD - Clobex Lotion), 0.05 per cent.

This medication is used to treat a variety of skin conditions like eczema, psoriasis, dermatitis, allergies and rash. Clobetasol helps in reducing the swelling, itching and redness problems that arises in these types of skin conditions. The lotion will be manufactured at the group's Topical manufacturing facility at Ahmedabad.

Ahmedabad-headquartered Zydus Cadila is one of the leading pharmaceutical companies of India. The group has manufacturing sites and research facilities spanning across Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and also in the US and Brazil. Since the origination of the filing process in FY 2003-04, the group now has 272 approvals and has so far filed over 360 ANDAs.

Zydus has a strong global presence in the regulated markets of the US, Europe (France and Spain) and in the high profile markets of Latin America and South Africa along with 25 other emerging markets worldwide. Zydus Cadila is the popular brand under the listed company Cadila Healthcare.

Shares of Cadila Healthcare had closed in BSE at Rs.245.80 as compared to the previous close of Rs. 249.20. The stock hit an intraday high of Rs. 250.90 and intraday low of 245.30.